Pareto Securities and Analysguiden publish research reports; Analysguiden increases price target to SEK 60

Report this content

Hørsholm, Denmark, November 19, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in November, following the publication of Q3 2021 results. Pareto upheld its ‘buy’ rating with a target price of SEK 68 per share, while Analysguiden has increased its fair value estimate from SEK 55 to SEK 60 per share, based on an increased likelihood of approval.

Both research reports are available on the Analyst Reports page of ExpreS2ion’s investor website. The next updates from Pareto Securities and Analysguiden are expected following major news.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732

For further information about ExpreS2ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869

Keith Alexander, CFO
Telephone: +45 5131 8147

About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines through its 34%-owned joint venture AdaptVac ApS. For additional information, please visit